ESMO Open

Article	Citations
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors	226
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches	216
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.	175
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat	157
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats	155
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia	137
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study	132
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations	127
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study	126
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology	122
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts	122
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer	110
Table of Contents	99
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced	95
Table of Contents	91
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids	91
Table of Contents	90
ESMO	86
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines	78
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap	74
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study	73
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles	69
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas	69
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study	68
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas	68

143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 2024	68
22P PillPal.ai: Using artificial intelligence to improve adherence to oral chemotherapy, TKIs, and CDK4/6 Inhibitors - A pilot study from a tertiary cancer centre in India	67
83P Efficacy and safety of KRAS G12C inhibitors across solid tumors: A systematic review and meta-analysis	66
152P Pregnancy after gestational trophoblastic neoplasia: Navigating fertility post-chemotherapy	65
43eP Is age a risk factor for locally advanced cervical cancer persistence?	65
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials	65
16eP Efficacy and safety of bevacizumab biosimilar in the treatment of brain metastases from breast cancer: A prospective, single-arm, multicentre, real-world study	65
Implementing SERENA6 in the clinic in the UAE: critical thinking of a community oncologist	64
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f	63
412TiP HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA	62
Editorial Board	58
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling	58
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations	56
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom	55
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer	55
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?	54
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma	54
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib	54
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)	53
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study	53
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas	53
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada	52
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study	52
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer	49
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis	48
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy	48
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response	48
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot	46
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials	45
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group	45
Editorial Board	45
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells	45
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression	44
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes	43
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience	43
Editorial Board	43
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio	43
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma	42
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–2020	42
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer	41
Editorial Board	40
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC	40
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis	40
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy	39
175P Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study	38
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study	38
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)	37
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials	37
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US	37
8P Unveiling functional reprogramming in pancreatic cancer: An integrative transcriptomic and explainable machine learning approach	36

58P Peripheral T cell phenotypes as predictors of progression and treatment response in mCRC: A prospective immunoprofiling study	36
Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?	36
36P Next-generation sequencing in liquid biopsy for advanced NSCLC: Indian tertiary cancer centre experience	36
338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial	34
Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)	34
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopaus	34
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single	34
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)	33
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer	33
90P Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+/HER2− metastatic breast cancer (mBC)	33
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection	33
PP474 Isoliensinine enhances therapeutic efficacy of paclitaxel and induces mitochondria-mediated cell death in multidrug-resistant colon cancer stem cells	33
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study	33
71P Relapse rate in patients avoiding adjuvant chemotherapy based on Oncotype DX score: Real-world data from three UK centres	32
307P Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial	32
357P BRCA genetic testing implementation and the impact of BRCA pathogenic variant status on clinical outcomes in HER2-negative metastatic and recurrent breast cancer in Japan	32
393P Treatment outcomes and toxicity of palbociclib in metastatic hormone receptor (HR)-positive HER2 -ve breast cancer patients: Real-life palbociclib outcome in Omani patients	32
238P Comparing the benefit-risk profiles of emerging treatments in early breast cancer (eBC) using the ESMO MCBS and the ASCO value framework	32
225P The impact of predictive genomic testing in Ireland: Financial and resource implications for healthcare institutions and patients	32
148P AI driven adjuvant therapy: Predicting pCR from radiological data in patients receiving incomplete NACT for LABC	32
420P Physicians’ knowledge, practice and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: Results of the ABC6 and ABC7 survey	32
334P The nationwide Advanced Breast Cancer - Patient Care Initiative (ABC-PCI): A medical oncologist-led survey on quality of life in Chinese patients with metastatic triple-negative breast cancer	32
211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation	31
438P Antidepressants/anxiolytics and breast cancer treatment: The case of drug-drug interactions	31
OP2-6 Favorable outcomes of EBV-associated gastric cancer treated with first-line immunotherapy plus chemotherapy: A multicenter real-world study	31
222P Hemoglobin A1c screening for patients with early breast cancer treated with adjuvant endocrine therapy	31
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer	31
72MO Homologous recombination deficiency (HRD) and genomic subgroup analysis in patients (pts) with platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine-gynx (MIRV) in the PICC	31
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]	30
An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore	30
Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies	30
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial	30
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance	30
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience	30
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients	30
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results	30
Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer	29
E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study	29
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations	29
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)	29
PP278 Role of cancer stem cells and inflammatory markers in the diagnosis and progression of prostate cancer	29
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study	29
547P From hospital to home: Pilot experience of home-based cancer immunotherapy delivery in an area of Bizkaia, Basque country	28
16P Dacomitinib in advanced NSCLC patients with uncommon EGFR mutations: A multicenter, single-arm, phase II study and biomarker analysis (DANCE study)	28
11MO First disclosure of efficacy and safety data for YL202/BNT326 (HER3 ADC) from a phase II trial in patients (pts) with non-small cell lung cancer (NSCLC)	28
17P Acquired BRAF V600E as bypass resistance to EGFR TKIs in EGFR-mutant NSCLC: A global multicenter cohort study	27
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)	27
491P Tumor treating fields (TTFields) augment antitumor and immune activity of immunochemotherapy in preclinical models of non-small cell lung cancer	27
465P An alternative strategy for lung cancer treatment: Targeting mTORC2	27
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage	26
225P Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients	26
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer	26
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients	26
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)	25
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients	25
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial	25
48P An AI System for accurate Ki-67 IHC assessment in breast cancer following the IKWG whole section global scoring protocol	25
Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series	24
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMAN	24
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target	24
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes	24
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers	24
Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study	24
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX	24
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication	24
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	24
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-re	23
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers	23
166P Hemin overcomes cetuximab resistance in colorectal cancer through ferroptosis	23
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets	23
442P Sacituzumab govitecan (SG) in patients (pts) with previously treated unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) within routine clinical practice in Spain: R	23
37P Fix the data, not the model: LMIC challenges in AI for precision oncology	23
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cance	23
526P An exploratory analysis of the relationship between oncotype score and the duration of response to first-line CDK4/6 inhibitors: Could we add this to our prognostication toolbox for metastatic br	23
12P Pan-tumor exDNA-targeting antibody platform enabling nuclear delivery for protein degradation	23
503P Efficacy and safety of the combination of trastuzumab (T), tucatinib (TUC), and oral vinorelbine (VNR) in patients (pts) with HER2+ metastatic breast cancer (MBC): Results from the TrasTUCAN (GEI	23
317TiP POP-ELA: a short-term preoperative, phase II, window-of-opportunity study, evaluating activity and safety of Elacestrant with and without ovarian function suppression (OFS) in premenopausal pat	22
280P Omitting chemotherapy (CT) in pN2-3, luminal A-like early breast cancer (eBC)	22
Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’	22
682P Implementation of a geriatric oncology care pathway for older patients with breast cancer in a regional public hospital in Portugal	22

130eP Programmed death-ligand 1 (PD-L1) immunohistochemical expression in triple-negative breast cancer: A clinicopathological study from a tertiary care center in South India	22
623P Patient navigation integrated into multidisciplinary breast cancer care: A prospective patient-reported evaluation from an LMIC center	22
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments	22
447P HER3 expression and overall survival (OS) in ICARUS-BREAST01: A phase II study with patritumab deruxtecan (HER3-DXd) patients (pts) with HR+/HER2- advanced breast cancer (ABC)	22
150eP High robustness and reproducibility of the genomic signature EndoPredict through quality control programs in France since 2017	22
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the rando	22
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	22
Psychiatric disorders in adolescent and young adult cancer survivors in Korea	21
283P Incidence of male breast cancer in genetically high-risk patients	21
439P The bio-psycho-social predictors of mental health among women with breast cancer	21
220P Efficacy and saftey of neoadjuvant trastuzumab, pyrotinib and chemotherapy in HER2-positive breast cancer: A real-world study	21
301MO Primary efficacy results of tremelimumab and durvalumab in combination with trastuzumab in trastuzumab resistant advanced HER2-positive breast cancer: BCT1703 DIAmOND	21
7P Unveiling the prognostic significance of protein expression in advanced high-grade serous ovarian cancer: A comparative study between long-term survivors and early mortal patients	21
481P Trends in mortality due to malignant and benign breast neoplasms in the United States from 2018 to 2023: A CDC wonder analysis	21
246P Four years of Oncotype DX test in clinical practice: the experience of the breast unit of University Hospital of Parma	21
229P Risk of recurrence and overall survival in Stage II and III ER+/HER2- early breast cancer: A population-based registry study in Sweden	21
131P Symptoms, fear of cancer recurrence and supportive care needs in gastrointestinal stromal tumor patients undergoing targeted therapy	21
6P vAO - Variant Annotator for OncoKB: A simplified interface to identify targeted therapies for somatic tumors	21
273P Clinicopathological features and outcomes in patients with BRCA-associated HR+/HER2- breast cancers eligible for adjuvant CDK4/6 and PARP inhibitors	21
23P Anti-tumor activity of novel Globo-H targeting CAR T cells in cholangiocarcinoma model	21
487P Health care provider’s adherence to clinical practice guidelines in diagnosing and staging breast cancer: An observational study	21
398P Evaluation of trastuzumab deruxtecan for metastatic HER2+ breast cancer: A meta-analysis	21
108P Biomarkers and personalized cancer therapy: A study of trial discontinuation and unpublished rates	21
430P Analysis of quality of life in a group of very long-term early stage breast cancer survivors	20
136P Vascular endothelial growth factor A (VEGF-A) expressions in invasive breast cancer and its association with lymph node metastasis and histopathologic features	20
178P Comparative study between wise pattern and non-vertical scar reduction mammoplasty	20
205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer	20
85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial	20
53P Tumor-agnostic detection and monitoring of circulating tumor DNA in HER2-positive early-stage breast cancer	20
134P Gene alterations in Mongolian breast cancer patients	20
24P The role of radiotherapy for intermediate-risk in early-stage cervical cancer post-radical hysterectomy: A meta-analysis	20
5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study	20
56P Neoadjuvant treatment with sequential letrozole and exemestane in postmenopausal patients with HR-positive, HER-2 negative breast cancer: Clinical and biomarker outcomes from the NEOLETEXE trial	20
120P Genetic associations of plasma proteins and breast cancer: Potential therapeutic drug candidates	20
37eP Local control with chemoradiotherapy in patients with metastatic cervical cancer	20
16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer	20
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study	19
Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?	19
153P Discovery of new BRCA1/2 mutations not described in the international breast consortium	19
Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)	19
30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy	19
108P Unravelling how different treatment sequences affect survival in osteosarcoma patients: A population-based study	19
73P TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma	19
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phas	19
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A	19
154P Alternative splicing in non-small cell lung cancer evolution	19
21P Squamous cell carcinoma arising from germ cell tumour of the ovary treated with immunotherapy	19
59P Delay in diagnosis of soft tissue sarcoma (STS): Contributing factors and their impact on overall survival - Experience from a tertiary care hospital	19
94P Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes	19
152P Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping	19
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis	19
Editorial Board	18
233P Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC)	18
76P Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression	18
142P Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early-stage triple-negative breast cancer (eTNBC)	18
296P Management of sexual dysfunction in breast cancer survivor women on adjuvant therapy	18
297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective	18
Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”	18
272P Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT study	18
93P Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world stud	18
65eP Real-world impact of pembrolizumab plus lenvatinib in metastatic uveal melanoma: A retrospective multicenter study	18
305P Role of the pan-immune-inflammatory value in stage III NSCLC treated with chemoradiotherapy with or without durvalumab	17
220eTiP A first-in-human, phase I study of XB010, a 5T4-MMAE ADC, in patients with non-small cell lung cancer (NSCLC) and other solid tumors	17
208eP Triple-targeted therapy with encorafenib, binimetinib and osimertinib in BRAF- and EGFR-co-mutated non-small cell lung cancer: A single-center experience	17
The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma	17
Molecular immune signature identifies microglia and NK cell infiltration as a favorable prognostic marker in adult-type high-grade glioma	17
191eTiP The Syrian TELE-TAT trial: A pragmatic, randomized study of tele-oncology for proactive adverse event management in patients receiving oral targeted therapies in a conflict zone	17
284P Clinical validation of CCR2-targeted SPECT imaging as a biomarker for monocyte-macrophage infiltration and prognosis in non-small cell lung cancer	17
189eP Prognostic value of CT-derived skeletal muscle quality in advanced NSCLC treated with immunotherapy-based regimens	17
439TiP ROSETTA Lung-01: A phase III, two-stage trial of pumitamig, a PD-L1 × VEGF-A bispecific antibody, plus chemotherapy versus atezolizumab + chemotherapy as first-line treatment in patients with e	17
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer	17
131P Mortality and economic burden associated with late-stage diagnosis of breast cancer	17
Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical O	17
532eP Co-mutation and compound mutation landscape in Indian lung carcinoma: A real-world NGS study of 118 patients	17
130P Randomized study of dexamethasone (DEX) administration methods for advanced lung cancer patients with anorexia (NJLCG1602/NEJ031)	17
18P Characterization and management of sevabertinib-induced diarrhea in the SOHO-01 study	17
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers	17
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis	17
34P DREAM: Data-driven drug repositioning through integrative analysis and machine learning	17
62MO Engineering CAR-NK cells with enhanced persistence and functionality for cancer immunotherapy	17
MAP 2025 Officers and Organisation	16
124P Melittin inhibits the growth of hepatocellular carcinoma Huh7 cells by downregulating LARS2 and ZNF19	16
46P The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis	16
89P Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients	16
Table of Contents	16
74P Evaluation of the clinical significance of rare epidermal growth factor receptor exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small cell lung cancer: A five-yea	16
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models	16
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression	16
17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs	16
52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)	16
425P Final analysis of the phase Ib-II trial of dendritic cell vaccination plus atezolizumab in ES-SCLC (VENEZOLUNG)	16
243P Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An all-Ireland patient-led survey (CTRIAL-IE 23-05)	16
132P Novel small molecule modulators for activation of mutant tumor suppressor p53	16
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC	16
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)	16